AI in Immuno Oncology Development

Artificial intelligence is transforming cancer research and drug development. BostonGene has partnered with Ottimo Pharma to accelerate development of a first in class immuno oncology therapy targeting PD1 and VEGFR2 pathways.

This collaboration uses advanced analytics and multiomic data to improve clinical development and precision medicine strategies.

Read more here:
https://bostongene.com/news-an....d-publications/news/

Artificial Intelligence Transforming Oncology Research

Artificial intelligence is rapidly reshaping cancer research and therapeutic development. BostonGene has announced a strategic collaboration with AstraZeneca to advance foundation model driven oncology development.


Read the complete collaboration announcement here:
https://bostongene.com/news-an....d-publications/news/

AI Validated for Precision HER2 Scoring in Breast Cancer

HER2 scoring is a critical biomarker assessment used in breast cancer treatment planning. An independent multi vendor study recently validated an AI driven approach for precision HER2 scoring. The study evaluated performance across multiple environments and demonstrated strong agreement with expert pathology interpretation.

Read the full BostonGene news article at https://bostongene.com/news-an....d-publications/news/

Tumor-associated macrophages and cancer-associated fibroblasts are studied in invasive lobular carcinoma vs no special type breast cancer using transcriptomic profiling to understand immune and stromal cell patterns across tumor subtypes.

Read the full article at https://bostongene.com/news-an....d-publications/publi